RxSight price target raised to $34 from $29 at Oppenheimer

Oppenheimer raised the firm’s price target on RxSight to $34 from $29 and keeps an Outperform rating on the shares. The firm notes the company’s Q2 sales of $20.8M were ahead of its/Street’s $19.0M/19.2M estimates, while sales guidance was raised again to $81M-$86M from $79-84M. Overall, momentum continued in the quarter with new customer acquisition coming in ahead of Oppenheimer’s expectations. Gross Margin is also on a positive trend with pathway to continued expansion on growing LAL scale, higher LAL mix and the higher margin LDD system coming in Q4, the firm adds.